Antibody-Drug Conjugates and Ocular Toxicity

Area of Science:

• Oncology
• Ophthalmology
• Pharmacology

Background:

• Antibody-drug conjugates (ADCs) are increasingly used for refractory cancers.
• ADCs utilize potent cytotoxins, leading to significant systemic side effects.
• Ocular toxicity is a notable and often severe adverse event associated with ADCs.

Purpose of the Study:

• To comprehensively review ocular toxicities associated with ADCs.
• To discuss reported mechanisms and clinical manifestations of ADC-induced ocular toxicity.
• To inform clinicians about managing ocular side effects in patients receiving ADCs.

Main Methods:

• Systematic literature review of ADCs and their ocular side effects.
• Analysis of published case reports and clinical studies focusing on ocular toxicity.
• Focus on ADCs with substantial published data and significant ocular impact.

Main Results:

• Common ocular toxicities include microcyst-like epithelial keratopathy and dry eye.
• Toxicity severity and incidence vary, with inconsistent evaluation and management methods.
• Specific ADCs demonstrate a higher propensity for ocular tissue damage.

Conclusions:

• Ocular toxicity is a critical concern in ADC therapy.
• Further research is needed to elucidate mechanisms and standardize management.
• Improved understanding and proactive strategies can mitigate ocular adverse events.